Paul Tudor Jones Aclaris Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 33,183 shares of ACRS stock, worth $95,898. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,183
Previous 33,183
-0.0%
Holding current value
$95,898
Previous $36,000
2.78%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ACRS
# of Institutions
84Shares Held
50.7MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$41.2 Million9.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$13.5 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$9.74 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$8.69 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$7.96 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $193M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...